Results of a large observational study provide more evidence that rosiglitazone increases cardiovascular risk.
Rosiglitazone and pioglitazone have been available for the treatment of diabetes since 1999, but questions remain about their safety. Using medical claims data from New Jersey (from 1999 through 2004) and Pennsylvania (from 1999 through 2005), investigators compared cardiovascular outcomes in patients who started taking rosiglitazone with outcomes in patients who started taking pioglitazone. For their primary analysis, the investigators assumed that all patients were exposed to the drug for 60 days after the date of their most recently filled prescriptions.
The study sample included 28,361 patients older than 65, evenly divided between new rosiglitazone and new pioglitazone users. The median exposure time, based on prescription supply, was 2…
Reviewing Author
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association